Loading…

Sign up or log in to bookmark your favorites and sync them to your phone or calendar.

Session 1: Enabling Drug Discovery: Target Validation to PreClinical [clear filter]
Wednesday, November 20
 

10:15am EST

Enabling Drug Discovery:Target Validation to PreClinical- Introduction
Sample management in the drug discovery space continues to evolve with the introduction of both non-small molecule modalities and new screening technologies . This session will provide case studies and outline best practices for tackling these new sample types and enabling downstream processes.

The following topics maybe covered in this session:
• Cell and gene therapy
• Biologics and peptides
• Automation and informatics challenges
• Workflow optimization
• Repurposing existing tools/processes




Chairs
M

Marybeth Burton

Executive Director, Discovery Sample Management, Merck


Wednesday November 20, 2019 10:15am - 10:20am EST
Essex South (3rd Floor) - Westin Copley 10 Huntington Avenue, Boston, MA 02116 USA

10:20am EST

Enabling Drug Discovery:Target Validation to PreClinical- Trends in Screening and Compound Profiling
Improving clinical success rates is a key objective in the pharmaceutical industry, and discovery science platforms continue to deploy new strategies aimed at improving success and translation to the clinic. As with others, we recognized that applying the more relevant cellular translational assays at the earliest points in discovery could allow better decisions earlier in the discovery process, and enable the identification of molecules with improved clinical translation In practice, this opportunity would not only be limited to primary cell or mixed cell culture based translational assays, but could also include broader use of organoids, spheroids, iPSC’s and edited cell lines. However, the costs, the complexity of biology, and especially the limited scalability of cells, limit how these can be used at a scale compatible with high-throughput plate-based HTS formats. We embarked on an ambitious campaign to evaluate ultra low volume platforms that would enable broader use of quantity-limited cell. These technologies have been a focus in the screening field for the past decade, so our work was aligned to evaluate these platforms for use in discovery. A key finding of our evaluation was that the biology is remarkably robust, and the fidelity of the biology was retained in most of the ultraminiaturized experiments. However, while many of the technologies show promise, these are not yet robust production platforms, and technologies for delivering compounds still needs to be addressed.

Speakers
avatar for Jeff Gross

Jeff Gross

Director of Screening, Profiling and Mechanistic Biology, GSK
Jeffrey Gross is a senior director with GlaxoSmithKline, and heads the Screening, Profiling, and Mechanistic Biology group in Upper Providence, PA.  He joined GSK in 2001 after a postdoctoral at the University of Wisconsin.  During his 18 years with GSK, he has worked in early discovery... Read More →

Chairs
M

Marybeth Burton

Executive Director, Discovery Sample Management, Merck


Wednesday November 20, 2019 10:20am - 10:40am EST
Essex South (3rd Floor) - Westin Copley 10 Huntington Avenue, Boston, MA 02116 USA

10:40am EST

Enabling Drug Discovery:Target Validation to PreClinical- Establishing Small Molecule Discovery at the Cleveland Clinic Lerner Research Institute
This presentation will discuss the newly formed Cleveland Clinic Center for Therapeutics Discovery (C3TD), its mission, model, and current status towards building a modern compound management and screening facility for investigators at the Lerner Research Institute.  At C3TD we embrace the strategic plan supporting our founder’s unifying three pillar mission:  care for the sick, investigate their problems, and educate our community. To be successful in contributing to our shared mission, assembled project teams leverage the most innovative approaches currently being explored for the treatment of human diseases and disorders and ‘de-risk’ to a point where these treatment strategies can directly impact patient care. By integrating high performance drug discovery resources and teams in the Lerner Research Institute, medicinal chemistry, molecular pharmacology, biochemistry, structural sciences, and drug metabolism and pharmacokinetics (DMPK) disciplines work together to illuminate and advance scientific breakthroughs beyond the traditional academic lab towards useful chemical probes and IND-ready assets.  Robust proven technologies in conjunction with best practices and protocols will be discussed in context of successes and lessons learned in prior academic drug discovery endeavors in neuroscience and oncology.

Speakers
avatar for Shaun Stauffer, Ph.D.

Shaun Stauffer, Ph.D.

Director, Cleveland Clinic Center for Therapeutics Discovery, Cleveland Clinic
Dr. Stauffer directs the newly formed Cleveland Clinic Center for Therapeutics Discovery initiated in 2018. He obtained his Ph.D. in organic chemistry 1999 from the University of Illinois Urbana-Champaign under John Katzenellenbogen and did post-doctoral studies with John Hartwig... Read More →

Chairs
M

Marybeth Burton

Executive Director, Discovery Sample Management, Merck


Wednesday November 20, 2019 10:40am - 11:00am EST
Essex South (3rd Floor) - Westin Copley 10 Huntington Avenue, Boston, MA 02116 USA

11:00am EST

Enabling Drug Discovery:Target Validation to PreClinical- Building on the Past and Preparing the Future of Lead Discovery through Screening and Compound Logistics at Roche pRED
This presentation  will cover the latest technological developments as well as plans for  screening and compound logistics processes at Hoffmann-La Roche Pharma  Research and Early Development (pRED) and how this opens new avenues for  finding new hits and leads.

Speakers
avatar for Nicolas Zorn, Ph.D.

Nicolas Zorn, Ph.D.

Head Compound Library Enhancement and Logistics, Hoffmann La Roche
Nicolas Zorn received his Ph.D. in Organic and Synthetic Chemistry from the University of Paris 6 and worked in the industry for ten years as a medicinal and then computational chemist across several disease therapeutic areas. He joined Roche in 2014 in the Computer Aided Drug Design... Read More →

Chairs
M

Marybeth Burton

Executive Director, Discovery Sample Management, Merck


Wednesday November 20, 2019 11:00am - 11:20am EST
Essex South (3rd Floor) - Westin Copley 10 Huntington Avenue, Boston, MA 02116 USA

11:20am EST

Enabling Drug Discovery:Target Validation to PreClinical-Pursuit of the One Day Turnaround: Expediting Process Support through Automated Sample Logistics
The development of monoclonal antibody (mAb) therapeutics requires fast turnaround of testing results to drive decision making during process development. Through the automation of routine testing assays, turnaround time has been reduced from 2 weeks to 1, yet laboratory processes are still hindered by preparative steps where samples are received, organized, and handled manually. By introducing new equipment, labware, and automated data handling, samples can be quickly processed through a myriad of product quality tests. These tools have further streamlined testing, reducing post-purification sample logistics to 1 hour and assay preparation to 30 minutes. These newfound efficiencies empower 1- to 2-day turnaround times, which further promote study design and impact in cell culture development.

Speakers
SJ

Sean Johnston

Sr Associate Scientist, Biogen

Chairs
M

Marybeth Burton

Executive Director, Discovery Sample Management, Merck


Wednesday November 20, 2019 11:20am - 11:40am EST
Essex South (3rd Floor) - Westin Copley 10 Huntington Avenue, Boston, MA 02116 USA